DK3681884T3 - Rad51-inhibitorer - Google Patents

Rad51-inhibitorer Download PDF

Info

Publication number
DK3681884T3
DK3681884T3 DK18782257.2T DK18782257T DK3681884T3 DK 3681884 T3 DK3681884 T3 DK 3681884T3 DK 18782257 T DK18782257 T DK 18782257T DK 3681884 T3 DK3681884 T3 DK 3681884T3
Authority
DK
Denmark
Prior art keywords
rad51 inhibitors
rad51
inhibitors
Prior art date
Application number
DK18782257.2T
Other languages
English (en)
Inventor
Alfredo C Castro
Joseph VACCA
Tyler Maclay
Casey Cameron Mccomas
Original Assignee
Cyteir Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyteir Therapeutics Inc filed Critical Cyteir Therapeutics Inc
Application granted granted Critical
Publication of DK3681884T3 publication Critical patent/DK3681884T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28Radicals substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/42Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK18782257.2T 2017-09-11 2018-09-11 Rad51-inhibitorer DK3681884T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762556763P 2017-09-11 2017-09-11
US201862711959P 2018-07-30 2018-07-30
PCT/US2018/050391 WO2019051465A1 (en) 2017-09-11 2018-09-11 RAD51 INHIBITORS

Publications (1)

Publication Number Publication Date
DK3681884T3 true DK3681884T3 (da) 2022-08-22

Family

ID=63722779

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18782257.2T DK3681884T3 (da) 2017-09-11 2018-09-11 Rad51-inhibitorer

Country Status (20)

Country Link
US (4) US10590122B2 (da)
EP (2) EP3681884B1 (da)
JP (1) JP7265537B2 (da)
CN (1) CN111542521B (da)
AU (1) AU2018328818C1 (da)
BR (1) BR112020004828A2 (da)
CA (1) CA3075062A1 (da)
DK (1) DK3681884T3 (da)
ES (1) ES2925218T3 (da)
HU (1) HUE059969T2 (da)
IL (2) IL273156B (da)
MX (2) MX2020002745A (da)
PH (1) PH12020550079A1 (da)
PL (1) PL3681884T3 (da)
PT (1) PT3681884T (da)
SG (2) SG10202107087YA (da)
SI (1) SI3681884T1 (da)
TW (1) TWI791608B (da)
WO (1) WO2019051465A1 (da)
ZA (1) ZA202104029B (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3069003A1 (en) 2017-07-11 2019-01-17 Cyteir Therapeutics, Inc. Rad51 inhibitors
EP3681884B1 (en) * 2017-09-11 2022-06-01 Cyteir Therapeutics, Inc. Rad51 inhibitors
MX2021010916A (es) * 2019-03-12 2021-10-01 Cyteir Therapeutics Inc Inhibidores rad51.
KR20210143257A (ko) * 2019-03-25 2021-11-26 사이티어 테라퓨틱스, 인크. Rad51 억제제와 parp 억제제의 조합
BR112021025491A2 (pt) * 2019-06-21 2022-04-26 Cyteir Therapeutics Inc Métodos para uso de inibidores de rad51 para tratamento de câncer pancreático
WO2021164746A1 (zh) 2020-02-19 2021-08-26 江苏先声药业有限公司 取代芳基类化合物
MX2022010963A (es) * 2020-03-03 2022-12-08 Cyteir Therapeutics Inc El compuesto 67a (2301085-06-1) inhibidor de rad51 en una dosificación específica para el tratamiento de cáncer.
JP2022151436A (ja) * 2021-03-26 2022-10-07 均 石井 髄膜炎と脳炎の治療薬。
CN116063243A (zh) * 2021-11-02 2023-05-05 上海旭成医药科技有限公司 芳香化合物、其制备方法、中间体、药物组合物和应用
CN116196314B (zh) * 2023-05-04 2023-08-15 广州市妇女儿童医疗中心 Ri-1或其盐在制备防治胃肠道疾病的药物中的应用
CN117603097B (zh) * 2023-11-29 2024-06-18 安徽泽升科技股份有限公司 一种快速制备2-溴-5-硝基苯磺酰氯的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
WO1992010588A1 (en) 1990-12-06 1992-06-25 Affymax Technologies N.V. Sequencing by hybridization of a target nucleic acid to a matrix of defined oligonucleotides
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US6309823B1 (en) 1993-10-26 2001-10-30 Affymetrix, Inc. Arrays of nucleic acid probes for analyzing biotransformation genes and methods of using the same
GB9507238D0 (en) 1995-04-07 1995-05-31 Isis Innovation Detecting dna sequence variations
PT2099442E (pt) * 2006-12-26 2015-02-10 Pharmacyclics Inc Métodos de utilização de inibidores de histona desacetilase e monitorização de biomarcadores em terapia de combinação
US8551984B2 (en) 2009-12-17 2013-10-08 Merck Sharp & Dohme Corp. Aminopyrimidines as SYK inhibitors
US10912761B2 (en) * 2012-11-30 2021-02-09 The University Of Chicago Methods and compositions involving RAD51 inhibitors
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
US10421753B2 (en) * 2015-03-02 2019-09-24 The Regents Of The University Of California RAD51 inhibitors and uses thereof
WO2016196955A1 (en) * 2015-06-04 2016-12-08 Drexel University Inhibitors of RAD52 Recombination Protein and Methods Using Same
CA3069003A1 (en) 2017-07-11 2019-01-17 Cyteir Therapeutics, Inc. Rad51 inhibitors
EP3681884B1 (en) 2017-09-11 2022-06-01 Cyteir Therapeutics, Inc. Rad51 inhibitors
MX2021010916A (es) 2019-03-12 2021-10-01 Cyteir Therapeutics Inc Inhibidores rad51.
KR20210143257A (ko) * 2019-03-25 2021-11-26 사이티어 테라퓨틱스, 인크. Rad51 억제제와 parp 억제제의 조합

Also Published As

Publication number Publication date
PT3681884T (pt) 2022-08-12
SI3681884T1 (sl) 2022-10-28
SG11202002069WA (en) 2020-04-29
JP2020533329A (ja) 2020-11-19
RU2020113064A (ru) 2021-10-14
US10336746B1 (en) 2019-07-02
TW201917121A (zh) 2019-05-01
AU2018328818B2 (en) 2023-07-06
RU2020113064A3 (da) 2022-04-29
IL293332B1 (en) 2023-10-01
ES2925218T3 (es) 2022-10-14
US11084812B2 (en) 2021-08-10
SG10202107087YA (en) 2021-07-29
TWI791608B (zh) 2023-02-11
AU2018328818C1 (en) 2023-12-21
HUE059969T2 (hu) 2023-01-28
CN111542521A (zh) 2020-08-14
US20190077799A1 (en) 2019-03-14
CN111542521B (zh) 2024-02-23
EP3681884B1 (en) 2022-06-01
PH12020550079A1 (en) 2020-10-05
IL273156B (en) 2022-07-01
BR112020004828A2 (pt) 2020-12-01
WO2019051465A1 (en) 2019-03-14
EP3681884A1 (en) 2020-07-22
PL3681884T3 (pl) 2022-11-14
CA3075062A1 (en) 2019-03-14
IL293332A (en) 2022-07-01
AU2018328818A1 (en) 2020-04-02
IL273156A (en) 2020-04-30
US10590122B2 (en) 2020-03-17
KR20200105808A (ko) 2020-09-09
IL293332B2 (en) 2024-02-01
EP4112616A1 (en) 2023-01-04
MX2023004221A (es) 2023-04-21
JP7265537B2 (ja) 2023-04-26
ZA202104029B (en) 2022-07-27
US20190194182A1 (en) 2019-06-27
US20220056022A1 (en) 2022-02-24
US20200216437A1 (en) 2020-07-09
MX2020002745A (es) 2020-10-14

Similar Documents

Publication Publication Date Title
DK3612525T3 (da) Pd-1-/pd-l1-inhibitorer
DK3497103T3 (da) Pyridopyrimdinon-cdk2/4/6-inhibitorer
DK3442972T3 (da) Bromdomænehæmmere
DK3681884T3 (da) Rad51-inhibitorer
DE202018003363U8 (de) Handgelenkssphygmomanometer
DK3672976T3 (da) Bcl-2-hæmmere
DK3571192T3 (da) Jak1-selektive inhibitorer
CL2018000524S1 (es) Golilla
MA46857A (fr) Inhibiteurs de magl
MA44006A (fr) Inhibiteur pde1
CU20160125A7 (es) Inhibidores de diacilglicerol aciltransferasa 2
MA46860A (fr) Inhibiteurs de magl
DK3630744T3 (da) Pyrazol-magl-inhibitorer
MA46855A (fr) Inhibiteurs de magl
MA43367A (fr) Inhibiteurs de métallo-bêta-lactamases
DK3186242T3 (da) Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
DK3341379T3 (da) EZH2-hæmmere
DK3114120T3 (da) Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere
MA46280A (fr) Inhibiteurs de la dopamine-b-hydroxylase
DK3280405T3 (da) Inhibitorer og anvendelser deraf
MA44607A (fr) Inhibiteurs de kinase
DK3481826T3 (da) Tyrosinkinaseinhibitorer
MA46889A (fr) Inhibiteurs de gsk-3
DK3519419T3 (da) Beta-lactamase-inhibitorer
DK3710457T3 (da) Immunproteasomhæmmere